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Abstract
Atrial fibrillation (AF) is a very common clinically significant arrhythmia noted in
clinical practice. Its incidence increases with age and along with advanced age, other
risk factors such hypertension, vascular disease, heart failure, diabetes, prior stroke and
female sex determine the associated stroke risk with AF. For over 40 years warfarin has
been the drug of choice used to reduce this stroke risk associated with AF. However,
the  narrow  therapeutic  range,  dietary  restrictions,  and  chronic  monitoring  with
warfarin  led  to  the  development  of  novel  oral  anticoagulants  (NOACs)  such  as
dabigatran, rivaroxaban, apixaban, and edoxaban. The purpose of this chapter is to
elucidate pharmacology and the clinical performance of these NOACs in the setting of
non-valvular atrial fibrillation (NVAF).
Keywords: novel oral anticoagulants, non-valvular atrial fibrillation, dabigatran, ri‐
varoxaban, apixaban, edoxaban, stroke prevention, atrial fibrilation
1. Introduction
Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice affecting
approximately 2.3 million people in the United States and 4.5 million people in Europe. The
incidence increases with age and the prevalence being 9% between the ages of 80 and 90 [1].
Other risk factors include hypertension, coronary artery disease, chronic obstructive pulmo‐
nary disease, valvular heart diseases or surgeries, hyperthyroidism and chronic alcoholism.
The mortality rate in AF is twice that of age-matched individuals in normal sinus rhythm, and
stroke risk is increased approximately fivefold in patients with non-valvular atrial fibrilla‐
tion (NVAF) [2].
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Over the last five decades, vitamin K antagonists (VKAs) such as warfarin have been the only
oral anticoagulants available for use as a long-term treatment to prevent strokes in patients
with AF. Aspirin (ASA) may be used for patients with NVAF who cannot take warfarin for
one reason or another, but ASA is much less effective than warfarin and is therefore recom‐
mended only for NVAF patients at low risk of stroke (CHA2DS2-VASc score of 0 or 1) in the
American College of Chest Physicians (ACCP) guidelines [2–4]. The CHA2DS2-VASc score is
an improvement on the CHADS2 score which has been widely used in clinical practice to risk
stratify patients with NVAF for stroke. The CHA2DS2-VASc added three risk factors, namely
age 65–74, female sex, and history of vascular disease [5]. However, the clinical trials for novel
oral anticoagulants (NOACs) were conducted prior to widespread implementation of the
CHA2DS2-VASc score, and thus, the risk stratification used in the trials is CHADS2.
Several historical placebo-controlled trials in subjects with AF were conducted with warfarin
between 1989 and 1999. A meta-analysis of these historical trials using a fixed effects model
showed that the relative risk reduction of stroke by warfarin was 62% (95% CI: 0.48, 0.72) with
an absolute risk reduction of 2.7% for primary prevention and 8.4% for secondary prevention
per year [2].
Although warfarin has been proven to be highly effective in preventing strokes, there have
been multiple issues such as periodic monitoring, dietary restrictions, medication restrictions
or interactions, and concerns for bleeding which render many patients with NVAF ineligible
to receive warfarin therapy. For example, a registry of patients discharged from hospital
revealed that only 54% of eligible AF patients received warfarin [6]. Likewise, surveys have
indicated that many patients with AF cannot or will not take warfarin. Only 10% of patients
with known AF who presented with an acute ischemic stroke had a therapeutic INR on
admission, and even in those AF patients with a prior history of stroke or transient ischemic
attack (TIA), only 18% had a therapeutic INR on admission [7]. Furthermore, studies show that
the risk of intracranial hemorrhage was more than twice that of patients taking aspirin [2].
Thus, there was a need to develop an anticoagulant that would have similar or better efficacy
as compared with warfarin along with better safety and more convenient management.
Dabigatran, rivaroxaban, apixaban, and edoxaban have been approved over the past five years
to satisfy this need.
2. Pharmacology
2.1. Mechanism of action
Dabigatran acts as a competitive reversible direct inhibitor of thrombin thereby preventing the
thrombin-dependent conversion of fibrinogen to fibrin in the coagulation cascade. Rivaroxa‐
ban, apixaban, and edoxaban are direct competitive inhibitors of factor Xa, thereby inhibiting
the formation of thrombin from prothrombin and downstream formation of fibrin from
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fibrinogen. And since factor Xa is located at the top of the final common coagulation pathway,
rivaroxaban, apixaban, and edoxaban can affect both the intrinsic and extrinsic coagulation
cascades. These target coagulation factors and other pharmacological parameters for each drug
are summarized in Table 1.
Characteristic Dabigatran Rivaroxaban Apixaban Edoxaban
Target Factor IIa Factor Xa Factor Xa Factor Xa
Molecular weight (Dal) 724 436 460 738
Ki (nmol/l) 4.6 0.4 0.08 0.56
Concentration to double PT
(μmol/l)
0.8 0.23 0.08 0.26
Concentration to double PTT
(μmol/l)
0.23 0.69 7.4 0.51
Reversible binding Yes Yes Yes Yes
Reversal of antithrombotic effect Specific antidote:
Idarucizumab
May consider PCC,
APCC, rFVIIa
May consider PCC,
APCC, rFVIIa
May consider
PCC, APCC,
rFVIIa
May consider PCC,
APCC, rFVIIa
Half-life (h) 12–17 5–9 12 10–14
Cmax (h) 1 2–4 3–4 1–2
Volume of distribution (l) 50–70 ~50 21 107
Protein binding 35% 92–95% 87% 55%
Renal excretion 80% 66% 27% 50%
Accumulation None None None None
Age effect None None Yes§ None
Sex effect None None None None
Body weight effect None None Yes Yes
Effect of food Yes* Yes None None
Primary hepatic clearance
pathway
No CYP3A4 CYP3A4 No
Pregnancy category C C B C
* Increases Cmax to 2 h but does not affect bioavailability.
§ Dosage reduction recommended if two of the following three risk factors present: body weight <60 kg, age >80 years
or serum creatinine >1.5 mg/dl.
Table 1. Pharmacokinetics and pharmacodynamics.
2.2. Absorption
Dabigatran itself is not absorbed via the oral route; however, its prodrug dabigatran etexilate
is rapidly absorbed (bioavailability 3–7%) via the oral route and is converted to the active
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ingredient by esterase-mediated hydrolysis in the liver. The absorption increases significantly
when the capsules are broken, and thus, the capsules should not be broken or chewed or
opened prior to administration. Additionally, when taken concomitantly with highly fatty
food, the time to maximal concentration (Cmax) increases from 1 to 2 h but the bioavailability
is not affected [8]. Rivaroxaban is rapidly absorbed in the proximal intestine with maximum
concentrations (Cmax) appearing 2–4 h after tablet intake with the absolute bioavailability of
80% for the 10 mg dose and 66% for the 20 mg dose. The bioavailability is decreased when the
drug is absorbed in the distal intestine or ascending colon [9]. This is an important consider‐
ation for patients with gastric bypass or other GI conditions that cause rapid transit. When
taken with food, both the Cmax and the bioavailability of rivaroxaban (for both 15 and 20 mg
doses) increases by 39 and 76%, respectively [9]. Thus, it is recommended that rivaroxaban be
taken with a large meal (ideally dinner) and not a light meal in order to slow down the transit
time.
Unlike the first two, apixaban is absorbed throughout the gastrointestinal tract, and therefore,
the drug displays a prolonged absorption which is not affected by food intake. The absolute
bioavailability of apixaban is 50% for doses up to 10 mg with a Cmax of 3–4 h. The distal small
bowel and ascending colon account for 55% of the absorption of apixaban. Thereby, making
it a better choice for patients with gastric bypass or other gastrointestinal conditions which
lead to rapid transit, whereas in patients with colectomies or Crohn’s disease, etc., apixaban’s
absorption may be altered and the drug may not be as readily available.
Edoxaban is also absorbed predominantly by the upper gastrointestinal tract with Cmax of 1–
2 h and bioavailability of 62%. The colon only accounts for 12% of absorption, thereby
rendering the absorption of the drug susceptible to conditions that cause rapid transit, similar
to rivaroxaban [10]. However unlike rivaroxaban, the absorption of edoxaban is not signifi‐
cantly affected by food intake.
2.3. P-glycoprotein transporter, cytochrome P-450 (CYP) enzymes, and drug interactions
The pro-drug dabigatran etexilate is a substrate for the efflux transporter P-glycoprotein (p-
GP) transporter. And even though it neither induces nor inhibits p-GP, potential co-adminis‐
tration of other drugs that inhibit or induce P-GP can affect its bioavailability. The
pharmacokinetics of dabigatran were not altered by another p-GP substrate digoxin, but an
inhibitor like pantoprazole decreased the bioavailability by 30% [11]. Since H2 blocker
ranitidine has no effect on the p-GP transporter, there was no effect on the area under the curve
(AUC) when dabigatran was co-administered. For other p-GP inhibitors such as dronedarone
or systemic ketoconazole, dosage adjustment was required in patients with reduced creatinine
clearance (30–50 ml/min) [8]. Other p-GP inhibitors such as amiodarone and verapamil only
modestly increased plasma concentrations (13 and 20%, respectively), and dose adjustment is
not required for these medications [11]. On the other hand, potent p-GP inducers such as such
as rifampin significantly reduced the AUC and Cmax of dabigatran and concomitant use
should therefore be avoided. Dabigatran is neither a substrate, nor an inducer or inhibitor of
CYP enzymes [8].
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Rivaroxaban is a substrate for p-GP transporter, CYP3A4/5 enzymes, and other transporters
such as ATP-binding cassette G2 [9]. Approximately 51% of orally administered rivaroxaban
is metabolized by the CYP enzymes 3A4 and 3A5. Thus, inhibition or induction of these
proteins can lead to changes in the bioavailability of the drug. When studied with rifampin or
phenytoin (p-GP and strong CYP3A4 inducers), the exposure to rivaroxaban decreased by
50%. Similarly, other combined strong p-GP, CYP3A4 inducers such as carbamazepine,
phenytoin, rifampin, and St. John’s wort should be avoided in patients taking rivaroxaban. For
drugs that are combined p-GP and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin,
and erythromycin) or a moderate CYP3A4 inhibitor (fluconazole), studies showed increases
in rivaroxaban exposure [9]. A dosage adjustment to 15 mg is required when taking these
medications concomitantly in patients with decreased creatinine clearance (CrCl 15–50 ml/
min). Additionally, rivaroxaban also has a low inhibitory effect on the p-GP transporter.
Regardless, there were no significant interactions with 7.5 mg single dose of midazolam
(substrate of CYP3A4), 0.375 mg once-daily dose of digoxin (substrate of p-GP), and 20 mg
once-daily dose of atorvastatin (substrate of CYP3A4 and p-GP) in healthy volunteers [12].
This is interesting because although neither dabigatran nor rivaroxaban has significant
interactions with digoxin, rivaroxaban may be a better choice for patients with severe ischemic
cardiomyopathy and NVAF because of an increased incidence of myocardial infarctions seen
with dabigatran (discussed later).
Like dabigatran, apixaban is also a substrate for p-GP efflux transporter but unlike dabigatran,
inhibition of p-GP transporter by itself does not affect the bioavailability. The drug is also
metabolized by CYP3A4 and co-administration with drugs that are strong inducers and
inhibitors for both p-GP and CYP3A4 increases the exposure to apixaban and raises the risk
of bleeding. Rifampin, carbamazepine, phenytoin, and St. John’s wort are strong combined
inducers of p-GP and CYP34A and thus concomitant use should be avoided due to reduced
exposure to apixaban. Ketoconazole, itraconazole, ritonavir, clarithromycin are strong dual
inhibitors of p-GP and CYP3A4 and thus can increase exposure to apixaban [13]. Dose
adjustment to 2.5 mg is recommended when apixaban is taken concomitantly with these
medications. If the patient is already on the reduced dose (2.5 mg) of apixaban for other reasons,
concomitant use of these medications is contraindicated [13]. Apixaban does not inhibit or
induce p-GP and its potential to inhibit or induce CYP enzymes is minimal and as such the
ability of apixaban to alter the exposure of co-administered drugs that are metabolites for these
enzymes is minimal.
Unlike rivaroxaban and apixaban, CYP enzymes only account for 4% of the exposure to
edoxaban. However, the intestinal p-GP transporter plays a significant role in clearance of the
drug and thus inhibition of the transporter leads to increased exposure. Clinical interaction
studies showed exposure to edoxaban increased by 87, 77, 53, 85, 73, 40, and 85% when used
concomitantly with ketoconazole, quinidine, verapamil, erythromycin, cyclosporine, amio‐
darone, and dronedarone, respectively [10]. Subsequently in ENGAGE trial, the edoxaban was
halved to 30 mg in patients who were taking verapamil, quinidine, or dronedarone [14]. And
in the HOKUSAI VTE study, the dose was reduced for patients taking verapamil, quinidine,
azithromycin, clarithromycin, erythromycin, itraconazole, or ketoconazole [15]. The use of
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edoxaban should be avoided when taking a potent p-GP inducer like rifampin, phenytoin,
carbamazepine, and St. John’s wort [16].
2.4. Elimination
In the phases II and III of the RE-LY trial, dabigatran was administered in oral, intramuscular,
and intravenous formulations. After oral administration of radiolabeled dabigatran, 82.6–
88.6% of radioactivity was recovered in the feces and 7% was recovered in the urine, the
remaining was attributed to incomplete absorption of dabigatran. Renal clearance of intrave‐
nous dabigatran was approximately 80%. After infusion, the total clearance of dabigatran was
found to be 92–141 ml/min, and the renal clearance was 81–106 ml/min showing that dabiga‐
tran is almost exclusively excreted via glomerular filtration and there was no secretion or
reabsorption further down the tubule [7, 13]. The terminal half-life was 12–17 h in healthy
individuals. The half-life was confounded by renal impairment and was increased to 15, 18,
and 27.2 h, respectively, in mild (50–80 ml/min), moderate (30–50 ml/min), and severe (15–30)
renal insufficiency. The total exposure (or AUC) also increased by approximately 1.5-, 3.2-, and
6.3-fold in mild, moderate, and severe renal impairment, respectively, when compared to
normal renal function. It is thus recommended that the dose of dabigatran for atrial fibrillation
be halved to 75 mg when the creatinine clearance (CrCl) is between 15 and 30 ml/min for and
the use of dabigatran should be avoided in patients with CrCl less than 15 ml/min or those on
dialysis [8]. Administration of dabigatran in patients with moderate (Child-Pugh class B) liver
impairment showed large inter-subject variability, but no evidence of a consistent change in
exposure or pharmacodynamics because the primary elimination pathway for dabigatran is
via the kidneys [8].
Off the orally administered radiolabeled rivaroxaban, 66% was recovered in the urine (36%
unchanged) and 28% was recovered in the feces (7%). The renal excretion of rivaroxaban is
primarily driven by active tubular secretion and secondarily by glomerular filtration in a 5:1
ratio. The terminal half-life is 5–9 h in healthy young individuals [9, 12]. Like dabigatran, the
exposure to rivaroxaban also increases by 44% for mild, 52% for moderate, and 66% for severe
renal impairment. As such, it is recommended that the dose of rivaroxaban for stroke preven‐
tion in NVAF be reduced to 15 mg orally with dinner in patients with moderate-to-severe renal
impairment (CrCl 15–50 ml/min) due to increased exposure and rivaroxaban should be
avoided in patients with CrCl <15 ml/min or those on dialysis. Rivaroxaban was not studied
in patients with severe (Child-Pugh class C) hepatic impairment, and exposure to rivaroxaban
increased by 15 and 127% in patients with Child-Pugh class A and B hepatic impairment [9].
Unlike dabigatran and rivaroxaban, apixaban is excreted in both urine and feces. Renal
excretion accounts for 27% of total clearance and biliary, and direct intestinal excretion
accounts towards the fecal elimination of apixaban. The terminal half-life is 12 h, and the
exposure is not significantly affected (<1.5× normal) for any level of renal impairment including
end-stage renal disease. Thus, no dosing adjustment is recommended kidney disease alone.
However, a dosage reduction of apixaban to 2.5 mg is recommended in patients that meet
another one of the following two risk factors: age >80 years or body weight <60 kg [13].
However, it should be noted that patients with end-stage renal disease (CrCl <15 ml/min) were
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not studied in the clinical efficacy and safety trials [16]. The recommendation for no dosage
adjustment is based on pharmacokinetic data showing a modest 17% increase in apixaban
exposure in patients receiving hemodialysis with an elimination via dialysis of 18 ml/min
reducing exposure of the drug by 14% postdialysis as compared to off dialysis period.
Similarly, in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impair‐
ment, the area under the curve or exposure did not change significantly as compared to normal
individuals and no dose adjustment is necessary in patients with Child-Pugh class A hepatic
impairment. However, since patients who have Child-Pugh class B hepatic impairment may
have intrinsic coagulation abnormalities, a recommendation on dosing cannot be made due to
limited clinical experience. Like the others, use of apixaban is not recommended in patients
with severe (Child-Pugh class C) hepatic impairment [13].
Edoxaban is excreted as unchanged drug in the urine with renal clearance accounting for 50%
of total clearance. Metabolism as well as biliary and intestinal excretion accounts for the
remaining clearance. The terminal half-life is 10–14 h. In a pharmacokinetic study, the total
systemic exposure to edoxaban increased by 32, 74, and 72% in patients with mild (50–80 ml/
min), moderate (30–50 ml/min), severe (15–30 ml/min) renal impairment, and by 93% in
patients receiving dialysis. Thus, a reduction in dose to 30 mg daily is recommended in patients
with CrCl 15–50 ml/min for stroke prevention in non-valvular atrial fibrillation [10, 16].
Interestingly, the incidence of stroke was higher in patients receiving edoxaban who had a
CrCl >95 ml/min as compared to warfarin in the clinical trial and the use of edoxaban is not
recommended in these patients [10, 14]. There were no significant differences for edoxaban in
patients with mild or moderate (Child-Pugh class A or B) hepatic impairment. A dose
adjustment is not necessary for Class A patients; however, once again due to the intrinsic
coagulation abnormalities in patients with class B hepatic impairment, the use of edoxaban is
not recommended [16].
2.5. Special populations
The pharmacokinetics and pharmacodynamics of both dabigatran and rivaroxaban are not
affected by age, gender, or body weight. There is no effect of ethnicity on the pharmacology
of dabigatran either, but rivaroxaban did have 20–40% higher exposure in patients of Japanese
ethnicity as compared to other ethnicities including Chinese [9]. This exposure was reduced
when it was corrected for body weight, but further studies may be required to assess clinical
implications to the use of rivaroxaban in the Japanese population specifically. Although
individually aged over 80 years and body weight <60 kg only modestly increased the exposure
to apixaban (<1.5× normal individuals), the combination of the two risk factors was deemed
to have a significant increase in the exposure of the drug. Thus, a reduced dose of 2.5 mg was
used in ARISTOTLE for patients who had two of the following three risk factors: age older
than 80 years, body weight <60 kg, and creatinine >1.5 mg/dl [13, 17]. Age is not a risk factor
for increased exposure of edoxaban but a phase II open-label study done in Japan revealed
that patients with total body weight <60 kg had double the bleeding risk as compared to
patients with total body weight >60 kg. Thus, in the phase III clinical trial, the dose of edoxaban
was reduced to 30 mg daily in patients with total body weight <60 kg [14, 16].
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Pharmacology and Phase III Clinical Trials
http://dx.doi.org/10.5772/64440
117
Dabigatran, rivaroxaban, and edoxaban are all under category C for pregnancy. Animal studies
showed increased maternal bleeding and increased fetal mortality with all three drugs. There
was decreased fetal implantation with dabigatran, and increased post-implantation loss, and
decreased fetal weight with rivaroxaban and edoxaban [8, 9, 16]. Additionally, there was
decrease in gall bladder size or absence of the organ with the use of edoxaban in animal studies.
Ten pregnancies were reported during the HOKUSAI VTE study, from which there were four
full-term births, two preterm births, one spontaneous abortion in the first trimester, and three
elective terminations during the study [15, 16]. In comparison, animal studies with apixaban
did not cause an increase in fetal toxicity, malformations, or mortality. There was an increase
in the rate of maternal bleeding at the rate of 19, 4, and 1 times, respectively, for mice, rats, and
rabbits with apixaban. As a result, the use of apixaban is under category B for pregnancy [13].
None of the NOACs are recommended for mothers who are breastfeeding, and the use of these
drugs has not been studied in the pediatric population.
3. Clinical trials
3.1. Trial designs
The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial was
designed as a non-inferiority trial to compare dabigatran to warfarin in 18, 113 patients from
951 clinical centers in 44 countries. Two doses of dabigatran; 110 and 150 mg were administered
in a double-blinded fashion [18]. We will discuss the data for the 150 mg dose of dabigatran
as FDA approval was only obtained for 150 and 75 mg (not studied) doses. The warfarin arm
was not blinded because the patients taking it needed regular follow-ups for INR control. The
semi-blinded design of RE-LY could leave the trial open to reporter bias. Thus, the authors of
the trial tried to minimize this bias by assigning two independent investigators who were
unaware of the treatment assignments, to adjudicate each event. In addition, all hospital
records were reviewed to ensure that all events were detected and correctly documented [18].
In contrast, the other three trials were designed in a double-blinded double dummy random‐
ized fashion to avoid reporter bias.
The Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF)
trial studied Warfarin in comparison with 20 mg of rivaroxaban in 14,264 patients from 1178
centers in 45 countries [19]. Similarly, the apixaban for Reduction in Stroke and Other Throm‐
boembolic Events in Atrial Fibrillation (ARISTOTLE) study enrolled 18,201 patients at 1034
sites in 39 countries and Effective Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) enrolled 21,105
patients from 1393 centers in 46 countries to study apixaban 5 mg and edoxaban 60 mg to
warfarin, respectively [14, 17].
Lower doses of NOACs were studied in ROCKET, ARISTOTLE, and ENGAGE. Rivaroxaban
15 mg was used for patients with creatinine clearance 15–50 ml/min [19]. For ARISTOTLE,
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apixaban dose was reduced to 2.5 mg twice daily if the patient had two of the following three
risk factors for increased bleeding: age ≥80 years, body weight ≤60 kg, or a serum creatinine
level ≥1.5 mg per deciliter [17]. In ENGAGE, randomization was done in 1:1:1 fashion for
warfarin, edoxaban 60 mg, and edoxaban 30 mg. The doses of edoxaban were further halved
to 30 and 15 mg for patients who either had a creatinine clearance 30–50 ml/min or body weight
≤60 kg thereby allowing a range of doses from 15 to 60 mg to be used in the study [14]. However,
the results of the study were more promising from the 60 mg dose with reduction to 30 mg for
specific patients leading to FDA approval. Thus, for the scope of this chapter, only the results
pertaining edoxaban 60 mg daily dose will be discussed.
Additionally, ROCKET-AF used both intention-to-treat and on-treatment analyses, and the
outcomes listed as number of events per 100 patient-years (instead of percent per year) [19].
To facilitate comparisons between trials, only the intention-to-treat analyses are reported in
this chapter. Similarly, ENGAGE also had a prespecified intention-to-treat analysis to assess
superiority to warfarin which was not statistically significant and thus will not be discussed
for the purposes of this chapter.
3.2. Patient populations
All four trials used similar criteria for enrolling and following patients with subtle differences
as listed in Table 2. However, these subtle differences may affect decision-making in different
clinical scenarios. For example, only ENGAGE included patients with prior bioprosthetic valve
or valve repair and as such edoxaban may be the preferred agent for stroke prevention in these
patients. Similarly, for newly diagnosed strokes, ARISTOTLE excluded patients with strokes
within 7 days of randomization. RE-LY, ROCKET, and ENGAGE excluded patients with
strokes within 6, 3, and 1 month, respectively. RE-LY and ROCKET also excluded patients with
transient ischemic attack (TIA) within 14 days and thus if a patient has had a stroke more than
7 days prior to and within 1 month of planned anticoagulation, apixaban may be the preferred
agent. ARISTOTLE also included patients with creatinine clearance less than 30 ml/min and
had the most patients in this category. As such in the absence of other risk factors for bleeding
and increased exposure to apixaban, the use of apixaban would be preferred in these patients.
Another important consideration is the CHADS2 score used in the trial, because higher scores
are associated with incrementally higher risk of stroke. Both ROCKET and ENGAGE required
a minimum CHADS2 score of 2 to be included in the trial. Additionally, ROCKET also
permitted patients with lower left ventricular ejection fractions, thus enrolling a higher risk
patient population than RE-LY and ARISTOTLE. Roughly one-third of patients in RE-LY and
ARISTOTLE had CHADS2 scores of 0 or 1, resulting in an overall 1% lower absolute risk of
stroke in those patients as compared to those enrolled in ROCKET or ENGAGE. Even though
the CHADS2 score was evenly distributed between the drug and warfarin groups were evenly
distributed in both trials, the overall incidence of primary outcome could be overestimated for
the ROCKET and ENGAGE trials.
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Characteristic RE-LY ROCKET ARISTOTLE ENGAGE
Drug Dabigatran Rivaroxaban Apixaban Edoxaban
Dosing 150 mg BID (75 mg) 20 mg daily (15 mg) 5 mg BID (2.5 mg)60 mg daily (30
mg)
Total population
(N)
18,113 14,266 18,206 21,105
Design PROBE Double blinded Double blinded Double blinded
Primary efficacy
endpoint
Stroke or systemic
embolism
Stroke or systemic
embolism
Stroke or
systemic
embolism
Stroke or
systemic
embolism
Primary safety
endpoint
Major bleeding Major bleeding or
clinically relevant non-
major Bleeding
Major bleeding Major bleeding
VKA naïve 50% 38% 43% 41%
Mean TTR for INR
during study
64 55 62 68
Inclusion criteria
AF criteria AF at screening or
within 6 months
AF recorded in 30 days
prior to randomization
and within 1 year
2 episodes of AF
or flutter
recorded 2 weeks
apart within 1
year
AF recorded
within 1 year
LVEF 40% or less 35% or less 40% or less NA
Exclusion criteria
Valve disease Hemodynamically
significant or prosthetic
Hemodynamically
significant or prosthetic
Moderate-severe
mitral stenosis or
prosthetic
Moderate-
severe mitral
stenosis or
mechanical§
Stroke Severe w/in 6 months
or TIA w/in 14 days
Severe w/in 3 months or
TIA w/in 14 days
Stroke w/in 7days Stroke w/in 30
days
Bleeding Surgery w/in 30 days,
GI bleed w/in 12
months, any
intracranial bleed,
severe hypertension
Surgery w/in 30 days, GI
bleed w/in 6mo, active
internal bleeding, any
intracranial bleed, dual
antiplatelet therapy,
severe hypertension,
platelet ≤90,000
Any intracranial
bleed, dual
antiplatelet
therapy, severe
hypertension
High risk for
bleeding, dual
antiplatelet
therapy
Patient demographics
Age (yrs) 71 71 70 72
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Characteristic RE-LY ROCKET ARISTOTLE ENGAGE
Male gender (%) 63.2 60.3 64.5 61.9
Type of atrial fibrillation (%)
Paroxysmal 32.6 17.5 15.1 25.4
Persistent/
permanent
67.4 82.5 84.9 74.6
CHADS2score (%)
I 32.2 0 34 0
II 35.2 13 35.8 46.8
III–VI 32.6 87 30.2 53.2
Comorbidities (%)
Hypertension 78.9 74 87.3 93.6
Previous TIA 20.3 54.9 19.2 28.3
Diabetes 23.1 40.4 25 36.2
Heart failure 31.8 62.6 35.5 57.5
Prior MI, CAD,
CABG
28 17.3 14.5 33.3
Medications (%)
ACE or ARB 66.7 55.1 70.9 65.9
Beta-blockers 63.7 65.1 63.6 66.3
Digoxin 28.7 38.8 32 30
Amiodarone 10.9 NA 11.1 11.8
Statins 43.9 42.9 45 47.8
Gastric antacids 17.9* NA 18.5 NA
NSAIDS 1.4 NA 8.2 1.1
Aspirin 38.7 36.3 31.3 29.3
Thienopyridine 5.5 NA 1.9 2.3
Creatinine clearance (%)
>80 ml/min 32 32.2 41.2 37.2
>50–80 ml/min 47.4 46.7 41.9 43
>30–50 ml/min 19.7 21.1 15 18.4
<30 ml/min 0.005 NA 1.5 0.76
* Total of proton pump inhibitors 13.9% and H2 antagonists 4%.
§ Bioprosthetic valves or valve repair patients were included.
Table 2. Study design and patient demographics.
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3.3. INR control
INR control is probably the most important factor in determining the non-inferiority of
NOACs. All trials used the Rosendaal method of total time in therapeutic range (TTR, reflecting
the percent of time the patient had an INR between 2 and 3) [20]. Overall, the TTR was 64% in
the RE-LY trial, 55% in ROCKET, 62% for ARISTOTLE, and 68% for ENGAGE. These numbers
clearly reflect that ROCKET had the least robust INR control in the warfarin arm leading to
significant criticism of the trial.
Although these data were not analyzed further in the primary publications, the heterogeneity
of INR management in the other trials appeared to impact clinical outcomes. In RE-LY, the
INR control in east and South-East Asia was worse than centers in Europe and North America.
The hazard ratio for major bleeding with dabigatran 150 mg was 1.24 (p = 0.03) when the TTR
was 68% or more [11]. Additionally, higher rates of both thromboembolic events and major
bleeds were seen with warfarin in centers with TTR <57%, even after adjusting for multiple
other potential confounding variables [21]. The inadequacy of INR control in Asia may explain
the more robust performance of dabigatran in those centers. Dabigatran 150 mg also performed
better than warfarin for a composite of stroke, systemic embolism, pulmonary embolism,
myocardial infarction, and cardiovascular death with a hazard ratio of 0.64 for TTR <57.1 and
hazard ratio of 1.19 for TTR 72.6 (p = 0.006). This trend was mirrored in the mortality rate where
dabigatran had an advantage at the centers with poor INR control (HR 0.67 vs 1.08, p = 0.052)
[21].
Similar to dabigatran, edoxaban also had lower efficacy in patients with higher TTR. The
hazard ratio for edoxaban 60 mg vs warfarin in TTR <57.7 was 0.8 compared to hazard ratio
of 1.07 for patients with TTR >73.9. TTR [10]. A different issue was noted in ROCKET-AF, the
TTR was low for the trial overall trial, and the resultant bleeding risks were equivalent between
rivaroxaban and warfarin. However, the centers in the USA where TTR was around 64%,
patients taking rivaroxaban suffered 2.5–3.7 more bleeds per stroke prevented as compared to
those taking warfarin [12]. Overall in patients with excellent INR control, warfarin may still
be the drug of choice for stroke prevention in atrial fibrillation.
3.4. Results and discussion
The primary outcome in all four trials was stroke or systemic embolism, and the primary safety
endpoint was major bleeding (RE-LY, ARISTOTLE, and ENGAGE), or combined major and
clinically important non-major bleeding events (ROCKET). As illustrated in Table 3, patients
randomized to the 150 mg dose of dabigatran in RE-LY had a reduction in the primary outcome,
experienced fewer ischemic as well as hemorrhagic strokes, and had a strong trend toward
lower all-cause mortality in spite of experiencing higher rates of myocardial infarction [18].
This trend for higher myocardial infarction leads to several meta-analyses which showed
approximately 30–40% increase in the rates of myocardial infarction with the use of dabigatran
as compared to control arms including enoxaparin, placebo, and warfarin [22, 23]. However,
in a post market analysis of 134,000 Medicare patients over 65 years of age done by the FDA
did not show any difference between the incidence of myocardial infarction between Dabiga‐
tran (15.7 per 1000 person years) and warfarin (16.9 per 1000 person years, p 0.92) [24]. None
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Clinical out‐
come
RE-LY ROCKET ARISTOTLE ENGAGE
Dabiga‐
tran 150
mg BID,
%/y
Warfar‐
in %/y
Hazard
ratio
p
value
Rivaroxa‐
ban 20 mg
QD, %/y
Warfar‐
in %/y
Hazard
ratio
p
value
Apixa‐
ban 5 mg
BID, %/y
Warfar‐
in %/y
Hazard
Ratio
p
value
Edoxa‐
ban high
dose %/y
Warfar‐
in %/y
Hazard
Ratio
p value
Stroke or SAE 1.11 1.69 0.66 <0.001 2.1 2.4 0.88 <0.001 1.27 1.6 0.79 0.01 1.18 1.5 0.79 <0.001
Stroke 1.01 1.57 0.64 <0.001 1.65 1.96 0.85 0.092 1.19 1.51 0.79 0.01 0.26 0.47 0.54 <0.001
Ischemic 0.92 1.2 0.76 0.03 1.34 1.42 0.94 0.581 0.97 1.05 0.92 0.42 1.25 1.25 1 0.97
Hemorrhagic 26.1 0.38 0.26 <0.001 0.26 0.44 0.59 0.024 0.24 0.47 0.51 <0.001 0.26 0.47 0.54 <0.001
Disabling 0.66 1 0.66 0.005 0.39 0.5 0.77 0.188 0.5 0.71 0.71 0.94 0.28 0.3 0.94 0.75
Non-disabling 0.37 0.58 0.62 0.01 0.79 0.77 1.03 0.863 0.81 1.01 0.8 0.044
Myocardial in‐
farction
0.74 0.53 1.38 0.048 0.91 1.12 0.81 0.121 0.53 0.61 0.88 0.37 0.7 0.75 0.94 0.6
Death from
vascular cause
2.28 2.69 0.85 0.04 1.53 1.71 0.89 0.289
All-cause mor‐
tality
3.64 4.13 0.88 0.051 1.87 2.21 0.85 0.073 3.52 3.94 0.89 0.047 3.8 4.35 0.87 0.006
Major bleeds 3.11 3.36 0.93 0.3 3.6 3.4 1.04 0.58 2.13 3.09 0.69 <0.001 2.75 3.43 0.8 <0.001
Intracranial
bleeds
0.3 0.74 0.4 <0.001 0.5 0.7 0.67 0.02 0.33 0.8 0.42 <0.001 0.38 0.85 0.47 <0.001
GI bleeds 1.51 1.02 1.5 <0.001 3.15* 2.16* <0.001 0.76 0.86 0.89 0.37 1.51 1.23 1.23 0.03
* Gastrointestinal bleeds in ROCKET-AF were reported as percentages and no Hazard ratio was reported, whereas all other outcomes in this trial were reported as
number per 100 patient-years.
Table 3. Efficacy outcomes.
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of the other NOAC had any signal towards myocardial infarction in their respective trials and
the choice of using an alternative agent to dabigatran in the setting of known coronary artery
disease should be individualized based on the clinical setting and physician discretion. There
was no difference in overall major bleeding, where a significant reduction in intracranial
hemorrhage was offset by a significantly higher rate of gastrointestinal bleeding.
For the intention-to-treat analyses in ROCKET-AF, rivaroxaban was noted to be non-inferior
(but not superior) to warfarin in reducing the primary endpoint [19]. The reduction in ischemic
stroke was not statistically significant as compared to the warfarin group and the outcomes
were driven by a significant reduction in hemorrhagic stroke by rivaroxaban which may be
reflective of the poor INR control in the trial. There was a trend toward reducing all-cause
mortality in ROCKET, and like RE-LY, an equivalent bleeding endpoint was driven by a
significant reduction of intracranial hemorrhage in the setting higher rates of gastrointestinal
bleeds. In comparison, apixaban was the only drug to show statistically significant reduction
in primary outcome compared to warfarin in both non-inferiority and superiority analyses.
And, like the other trials, the reduction in the primary outcome was driven by a significant
reduction of hemorrhagic strokes [17]. ENGAGE did show non-inferiority to warfarin in the
reduction of primary outcomes, but in the prespecified superiority analysis, the difference was
not statistically significant [14]. Unlike the prior studies of dabigatran and rivaroxaban, both
ARISTOTLE and ENGAGE demonstrated a statistically significant reduction in all-cause
mortality and major bleeding with the study drugs in comparison to warfarin [14, 17].
However, only apixaban showed no significant increase in gastrointestinal bleeding among
all NOACs and it should be considered as the agent of choice in patients with prior (or at high
risk for) gastrointestinal bleeding.
4. Conclusion
The approval of NOACs for stroke prevention in patients with NVAF has ushered a new era
in this field with a multitude of options available for practitioners. Warfarin still may be the
drug of choice in several clinical situations such as compliant patients with good INR control
or those with valvular heart disease, etc. However, patient preference and the ease of use have
made NOACs the preferred initial agent for stroke prevention in patients with NVAF. The
subtle differences between the NOACs described throughout this chapter are aimed at
providing an improved understanding of the intricacies with which these medications perform
in the human body and thereby help guide decision-making.
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